These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 32825960)

  • 1. Expression level of PD-L1 is involved in ALDH1A1-mediated poor prognosis in patients with head and neck squamous cell carcinoma.
    Zhou AL; Wang X; Yu W; Yang L; Wei F; Sun Q; Wang Y; Kou F; Dong R; Ren X; Zhang X
    Pathol Res Pract; 2020 Sep; 216(9):153093. PubMed ID: 32825960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of PD-1/PD-L1 in head and neck squamous cell carcinoma and its clinical significance.
    Chen SW; Li SH; Shi DB; Jiang WM; Song M; Yang AK; Li YD; Bei JX; Chen WK; Zhang Q
    Int J Biol Markers; 2019 Dec; 34(4):398-405. PubMed ID: 31674884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of cancer stem cell marker expression in primary head and neck squamous cell carcinoma shows prognostic value for aldehyde dehydrogenase (ALDH1A1).
    Szafarowski T; Sierdziński J; Ludwig N; Głuszko A; Filipowska A; Szczepański MJ
    Eur J Pharmacol; 2020 Jan; 867():172837. PubMed ID: 31811857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
    Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
    Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas.
    Sanchez-Canteli M; Granda-Díaz R; Del Rio-Ibisate N; Allonca E; López-Alvarez F; Agorreta J; Garmendia I; Montuenga LM; García-Pedrero JM; Rodrigo JP
    Cancer Immunol Immunother; 2020 Oct; 69(10):2089-2100. PubMed ID: 32448984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TLR9 Mediated Tumor-Stroma Interactions in Human Papilloma Virus (HPV)-Positive Head and Neck Squamous Cell Carcinoma Up-Regulate PD-L1 and PD-L2.
    Baruah P; Bullenkamp J; Wilson POG; Lee M; Kaski JC; Dumitriu IE
    Front Immunol; 2019; 10():1644. PubMed ID: 31379843
    [No Abstract]   [Full Text] [Related]  

  • 7. SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Pai SI; Cohen EEW; Lin D; Fountzilas G; Kim ES; Mehlhorn H; Baste N; Clayburgh D; Lipworth L; Resteghini C; Shara N; Fujii T; Zhang J; Stokes M; Wang H; Twumasi-Ankrah P; Wildsmith S; Khaliq A; Melillo G; Shire N
    J Transl Med; 2019 Dec; 17(1):429. PubMed ID: 31878938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of poliovirus receptor is associated with poor prognosis in head and neck squamous cell carcinoma patients.
    Lim SM; Hong MH; Ha SJ; Hwang D; Chae S; Koh YW; Choi EC; Kim SH; Kim DH; Yoon SO; Kim HR
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2741-2750. PubMed ID: 33616718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of quantum dot technology with conventional immunohistochemistry in examining aldehyde dehydrogenase 1A1 as a potential biomarker for lymph node metastasis of head and neck cancer.
    Xu J; Müller S; Nannapaneni S; Pan L; Wang Y; Peng X; Wang D; Tighiouart M; Chen Z; Saba NF; Beitler JJ; Shin DM; Chen ZG
    Eur J Cancer; 2012 Jul; 48(11):1682-91. PubMed ID: 22341992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of ALDH1A1-positive cancer stem cells in patients with locally advanced, metastasized head and neck squamous cell carcinoma.
    Qian X; Wagner S; Ma C; Coordes A; Gekeler J; Klussmann JP; Hummel M; Kaufmann AM; Albers AE
    J Cancer Res Clin Oncol; 2014 Jul; 140(7):1151-8. PubMed ID: 24770634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The let-7 family of microRNAs suppresses immune evasion in head and neck squamous cell carcinoma by promoting PD-L1 degradation.
    Yu D; Liu X; Han G; Liu Y; Zhao X; Wang D; Bian X; Gu T; Wen L
    Cell Commun Signal; 2019 Dec; 17(1):173. PubMed ID: 31881947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of PD-L1 expression in pulmonary metastases from head and neck squamous cell carcinoma.
    Okada S; Itoh K; Ishihara S; Shimada J; Kato D; Tsunezuka H; Miyata N; Hirano S; Teramukai S; Inoue M
    Surg Oncol; 2018 Jun; 27(2):259-265. PubMed ID: 29937180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
    Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
    Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics and impact of programmed death-ligand 1 expression, CD8+ tumor-infiltrating lymphocytes, and p16 status in head and neck squamous cell carcinoma.
    Ngamphaiboon N; Chureemas T; Siripoon T; Arsa L; Trachu N; Jiarpinitnun C; Pattaranutaporn P; Sirachainan E; Larbcharoensub N
    Med Oncol; 2019 Jan; 36(2):21. PubMed ID: 30666437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
    Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
    Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia dynamics on FMISO-PET in combination with PD-1/PD-L1 expression has an impact on the clinical outcome of patients with Head-and-neck Squamous Cell Carcinoma undergoing Chemoradiation.
    Rühle A; Grosu AL; Wiedenmann N; Mix M; Stoian R; Niedermann G; Baltas D; Werner M; Weber WA; Kayser G; Nicolay NH
    Theranostics; 2020; 10(20):9395-9406. PubMed ID: 32802199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined approach for predicting the efficacy of nivolumab in head and neck carcinoma by tissue and soluble expressions of PD-L1 and PD-L2.
    Sato R; Komatsuda H; Inoue T; Wakisaka R; Kono M; Yamaki H; Ohara K; Kumai T; Kishibe K; Hayashi T; Takahara M
    Head Neck; 2024 Sep; 46(9):2233-2243. PubMed ID: 38665131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas.
    Succaria F; Kvistborg P; Stein JE; Engle EL; McMiller TL; Rooper LM; Thompson E; Berger AE; van den Brekel M; Zuur CL; Haanen J; Topalian SL; Taube JM
    Cancer Immunol Immunother; 2021 May; 70(5):1227-1237. PubMed ID: 33125511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Negative prognostic behaviour of PD-L1 expression in tongue and larynx squamous cell carcinoma and its significant predictive power in combination with PD-1 expression on TILs.
    Ahmadvand S; Norouzi LA; Mohammadi Y; Safaei A; Khademi B; Motiee-Langroudi M; Ghaderi A
    BMC Immunol; 2024 Jan; 25(1):7. PubMed ID: 38229027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
    Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
    J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.